GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius SE & Co KGaA (WBO:FRE) » Definitions » Debt-to-EBITDA

Fresenius SE KGaA (WBO:FRE) Debt-to-EBITDA

: 4.92 (As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fresenius SE KGaA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2,581 Mil. Fresenius SE KGaA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €13,249 Mil. Fresenius SE KGaA's annualized EBITDA for the quarter that ended in Dec. 2023 was €3,216 Mil. Fresenius SE KGaA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 4.92.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Fresenius SE KGaA's Debt-to-EBITDA or its related term are showing as below:

WBO:FRE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.63   Med: 3.64   Max: 8.96
Current: 4.07

During the past 13 years, the highest Debt-to-EBITDA Ratio of Fresenius SE KGaA was 8.96. The lowest was 2.63. And the median was 3.64.

WBO:FRE's Debt-to-EBITDA is ranked worse than
67.07% of 416 companies
in the Healthcare Providers & Services industry
Industry Median: 2.56 vs WBO:FRE: 4.07

Fresenius SE KGaA Debt-to-EBITDA Historical Data

The historical data trend for Fresenius SE KGaA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius SE KGaA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.76 3.60 3.91 8.96 5.81

Fresenius SE KGaA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.64 4.66 5.65 10.92 4.92

Competitive Comparison

For the Medical Care Facilities subindustry, Fresenius SE KGaA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresenius SE KGaA Debt-to-EBITDA Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fresenius SE KGaA's Debt-to-EBITDA falls into.



Fresenius SE KGaA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fresenius SE KGaA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2581 + 13249) / 2727
=5.80

Fresenius SE KGaA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2581 + 13249) / 3216
=4.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Fresenius SE KGaA  (WBO:FRE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Fresenius SE KGaA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fresenius SE KGaA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresenius SE KGaA (WBO:FRE) Business Description

Address
Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius SE is a healthcare holding company based in Germany with four segments. The company owns a large stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals and fertility clinics in Germany, Spain, and Latin America. Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.

Fresenius SE KGaA (WBO:FRE) Headlines

No Headlines